Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Sitagliptin and metformin

(Janumet®)

Janumet®

Drug updated on 11/1/2024

Dosage FormTablet (oral; sitagliptin/metformin hydrochloride 50 mg/500 mg); Tablet (oral; sitagliptin/metformin hydrochloride 50 mg/1000 mg)
Drug ClassDipeptidyl peptidase-4 (DPP-4) inhibitors and biguanides
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Semaglutide (Adults with Type 2 Diabetes): Showed a significant reduction in HbA1C (WMD (weighted mean difference): -0.98; 95% CI (confidence interval): -1.28, -0.69; p < 0.0001), systolic (WMD: -3.73; 95% CI: -5.42, -2.04; p < 0.0001) and diastolic blood pressure (WMD: -0.66; 95% CI: -1.02, -0.29; p = 0.0005), and body weight (WMD: -3.17; 95% CI: -3.84, -2.49; p < 0.00001) compared to Sitagliptin.
  • Pediatric HbA1C Reduction (Children and Adolescents with Type 2 Diabetes): Saxagliptin+Metformin (MD (mean difference) -1.91%; CI: -2.85%, -0.97%), Liraglutide+Metformin (MD -1.45%; CI: -1.65%, -1.26%), and Liraglutide alone (MD -0.90%; CI: -1.35%, -0.45%) showed notable HbA1C reductions.
  • Semaglutide in adults was associated with a higher risk of total adverse events, increased pulse rate (WMD: 3.33; 95% CI: 1.61, 5.06; p < 0.00001), and more frequent premature treatment discontinuation compared to Sitagliptin, with no significant differences in the risk of serious, severe, moderate, or mild adverse events.
  • In children and adolescents, no significant differences were noted in adverse events among treatments, except for Liraglutide+Metformin, which was linked to significant adverse effects such as abdominal pain.
  • The population types in the reviewed evidence include adults with type 2 diabetes inadequately controlled with metformin and children and adolescents aged 10-17 years with type 2 diabetes.